American Journal of Cardiology
Volume 102, Issue 5 , Pages 588-592 , 1 September 2008

Cost of Preimplantation Cardiac Imaging in Patients Referred for a Primary-Prevention Implantable Cardioverter-Defibrillator

  • Andrew D. Krahn, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of Western Ontario, London, Ontario, Canada
    • Corresponding Author InformationCorresponding author: Tel: 519-663-3746; Fax: 519-663-3786
    • ,
  • Jeffrey S. Hoch, PhD

      Affiliations

    • Centre for Research on Inner City Health, The Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Marie Antoinette Rockx, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of Western Ontario, London, Ontario, Canada
    • ,
  • Peter Leong-Sit, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of Western Ontario, London, Ontario, Canada
    • ,
  • Lorne J. Gula, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of Western Ontario, London, Ontario, Canada
    • ,
  • Raymond Yee, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of Western Ontario, London, Ontario, Canada
    • ,
  • Allan C. Skanes, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of Western Ontario, London, Ontario, Canada
    • ,
  • George J. Klein, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of Western Ontario, London, Ontario, Canada

Received 29 December 2007 ,Revised 17 April 2008 ,Accepted 17 April 2008.

References 

  1. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, et al ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation. 2002;106:2145–2161
  2. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  3. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48:e247–e346
  4. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia (Multicenter Automatic Defibrillator Implantation Trial Investigators). [see comments] N Engl J Med. 1996;335:1933–1940
  5. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  6. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease (Multicenter Unsustained Tachycardia Trial Investigators). N Engl J Med. 1999;341:1882–1890
  7. Tang AS, Ross H, Simpson CS, Mitchell LB, Dorian P, Goeree R, et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. Can J Cardiol. 2005;21(suppl A):S11–S18
  8. Buxton AE. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? (Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator). Circulation. 2005;111:2537–2549
  9. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction (Results of the Survival And Ventricular Enlargement Trial. The SAVE Investigators). N Engl J Med. 1992;327:669–677
  10. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–2158
  11. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488
  12. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310
  13. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658
  14. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF) (MERIT-HF Study Group). JAMA. 2000;283:1295–1302
  15. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  16. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al Recommendations for quantitation of the left ventricle by two-dimensional echocardiography (American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms). J Am Soc Echocardiogr. 1989;2:358–367
  17. Gottsauner-Wolf M, Schedlmayer-Duit J, Porenta G, Gwechenberger M, Huber K, Glogar D, et al. Assessment of left ventricular function: comparison between radionuclide angiography and semiquantitative two-dimensional echocardiographic analysis. Eur J Nucl Med. 1996;23:1613–1618
  18. Nichols KJ, Bacharach SL, Bergmann SR, Cullom SJ, Ficaro EP, Galt JR, et al. Instrumentation quality assurance and performance. J Nucl Cardiol. 2006;13:e25–e41
  19. Schwarz KQ, Bezante GP, Chen X, Villa G, Brunelli C. Contrast harmonic color Doppler left ventriculography: machine-interpreted left ventricular ejection fraction compared with equilibrium-gated radionuclide ventriculography. J Am Soc Echocardiogr. 2000;13:368–378
  20. van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol. 1996;77:843–850
  21. Agresti A, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat. 1988;52:119–126
  22. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471–1480
  23. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT (Multicenter Automatic Defibrillator Implantation Trial). Circulation. 1998;97:2129–2135
  24. Sheldon R, O'Brien BJ, Blackhouse G, Goeree R, Mitchell B, Klein G, et al. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation. 2001;104:1622–1626
  25. Lynd LD, O'Brien BJ. Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence. J Cardiovasc Electrophysiol. 2003;14(suppl):S99–S103
  26. Larsen G, Hallstrom A, McAnulty J, Pinski S, Olarte A, Sullivan S, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation. 2002;105:2049–2057
  27. O'Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103:1416–1421
  28. Stanton MS, Bell GK. Economic outcomes of implantable cardioverter-defibrillators. Circulation. 2000;101:1067–1074
  29. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT (Multicenter Automatic Defibrillator Implantation Trial). Circulation. 1998;97:2129–2135
  30. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol. 2004;44:2166–2172

 Dr. Krahn was supported by Grant NA3397 from the Heart and Stroke Foundation of Ontario, Ottawa, Ontario, Canada.

PII: S0002-9149(08)00746-7

doi: 10.1016/j.amjcard.2008.04.067

American Journal of Cardiology
Volume 102, Issue 5 , Pages 588-592 , 1 September 2008

Article Tools

* Image Usage & Resolution